EN
Enovis Corporation
ENOV · NYSE
$17.95 -1.51% (-$0.28)
1M -27.49%
Market Cap $1.03B
P/E Ratio -
Div. Yield -
ROE 68.17%
Bulios Fair Price
$24.94
39.0% upside
Current Price
$17.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ENOV is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
90 /100
Cheap P/FCF 16.23x
P/S 0.45x
P/B 0.70x
Growth
61 /100
Stable Book val. growth 24.40%
Rev. growth 12.88%
FCF growth N/A
Profitability
32 /100
Weak Op. margin 4.14%
Gross margin 57.43%
FCF margin 2.77%
Quality
13 /100
Poor ROA 29.25%
ROIC 3.04%
Asset turnover 0.61x
Debt
48 /100
Moderate Int. coverage -18.23x
Debt/Equity 0.93x
Current ratio 1.98x
Stability
39 /100
Moderate EPS volatility 1,310.45%
Beta 1.43x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ENOV
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Damien McDonald
Employees
7,802
Headquarters
Wilmington
Upcoming events
05 NOV
Earnings
Upcoming earnings report